Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection

The hepatitis C virus (HCV) is potentially associated with liver cancer, and advances in various drugs have led to progress in the treatment of hepatitis C and attempts to prevent its transition to liver cancer. Furthermore, reactivation of HCV has been observed in the treatment of lymphoma, during...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-05, Vol.15 (10), p.2852
Main Authors: Tsutsumi, Yutaka, Ito, Shinichi, Shiratori, Souichi, Teshima, Takanori
Format: Article
Language:English
Subjects:
African Americans
Antiviral agents
B-cell lymphoma
Biomarkers
Chemotherapy
Epidemiology
Hepatitis B
Hepatitis C
Immortalization
Infections
Liver cancer
Lymphocytes
Lymphocytes B
Lymphoma
Malignancy
Pathogenesis
Prognosis
Review
Ribonucleic acid
RNA
RNA viruses
White people
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The hepatitis C virus (HCV) is potentially associated with liver cancer, and advances in various drugs have led to progress in the treatment of hepatitis C and attempts to prevent its transition to liver cancer. Furthermore, reactivation of HCV has been observed in the treatment of lymphoma, during which the immortalization and proliferation of lymphocytes occur, which leads to the possibility of further stimulating cytokines and the like and possibly to the development of lymphoid malignancy. There are also cases in which the disappearance of lymphoid malignancy has been observed by treating HCV and suppressing HCV-Ribonucleic acid (RNA), as well as cases of recurrence with an increase in HCV-RNA. While HCV-associated lymphoma has a poor prognosis, improving the prognosis with Direct Acting Antivirals (DAA) has recently been reported. The reduction and eradication of HCV-RNA by means of DAA is thus important for the treatment of lymphoid malignancy associated with HCV infection, and HCV-RNA can presumably play a role as a biomarker. This review provides an overview of what is currently known about HCV-associated lymphoma, its epidemiology, the mechanisms underlying the progression to lymphoma, its treatment, the potential and limits of HCV-RNA as a therapeutic biomarker, and biomarkers that are expected now that DAA therapy has been developed.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15102852